INTERNATIONAL SYMPOSIUM ON POLIOMYELITIS CONTROL

Participants

Preface

SESSION I: CURRENT STATUS OF POLIOMYELITIS

F. Assaad and K. Ljungars-Esteves

Nan Goldblum and Tiberio Swartz

Samuel Ofosu-Amaah

V. P. Grachev

World Overview of Poliomyelitis: Regional Patterns and Trends

Epidemiologic Aspects of Poliomyelitis Eradication

The Israeli Experience in the Control of Poliomyelitis During a Quarter of a Century, 1957-1982

The Challenge of Poliomyelitis in Tropical Africa

Long-Term Use of Oral Poliovirus Vaccine from Sabin Strains in the Soviet Union

SESSION II: POLIOVIRUS VACCINES

J. Melnick

R. J. Vallancourt

L. Spence

A. J. Beale

Live Attenuated Vaccine

Live Attenuated Oral Poliovirus Vaccine

Current Poliovirus Vaccines

Observations on the Use of Oral Poliovirus Vaccines in the Caribbean and Canada

Live Attenuated Oral Poliovirus Vaccine: Problem Areas in Production

Formalin-Inactivated Vaccine

Inactivated Poliovirus Vaccine: Current Production Methods and New Developments

Industrial-Scale Production of Inactivated Poliovirus Vaccine Prepared by Culture of Vero Cells on Microcarrier

Inactivated Poliovirus Vaccine and Test Development at Connaught Laboratories Ltd.

Two Injections of Diphtheria-Tetanus-Pertussis-Polio Vaccine as the Backbone of a Simplified Immunization Schedule in Developing Countries

Modes of Action of and Response to Vaccines

Modes of Action of Poliovirus Vaccines and Relation to Resulting Immunity
Use of Inactivated Vaccine

One-Dose Immunization Against Paralytic Poliomyelitis Using a Noninfectious Vaccine

Surveillance and Control of Poliomyelitis in The Netherlands

Elimination of Poliomyelitis in Finland

Inactivated Poliovirus Vaccine in Finland

Use of Killed Poliovirus Vaccine in a Routine Immunization Program in West Africa

Use of Both Attenuated and Inactivated Vaccines

Successful Results of a Program Combining Live and Inactivated Poliovirus Vaccines to Control Poliomyelitis in Gaza

Vaccination with Inactivated Poliovirus Vaccine and Oral Poliovirus Vaccine in Denmark

World Health Organization Programs

The Expanded Programme on Immunization of the World Health Organization

Consequences of the Introduction of the New Inactivated Poliovirus Vaccine into the Expanded Programme on Immunization

Strategies for Control: A Discussion

SESSION IV: CURRENT RESEARCH

Molecular Genetics of Poliovirus

Nucleotide Sequence from Neurovirulent and Attenuated Strains of Type 3 Poliovirus

Approaches to the Development of New Poliovirus Vaccines Based on Molecular Genetics

Molecular Epidemiology of Polioviruses

Peptide Priming of a Poliovirus Neutralizing Antibody Response

Antigenic Characterization of Poliovirus Type 3 Using Monoclonal Antibodies

Studying Poliovirus with Infectious Cloned cDNA

Identification of an Antigenic Site in the Neutralization of Type 3 Poliovirus

Standardization of Safety and Potency Tests of Vaccines Against Poliomyelitis
FRANK T. PERKINS  
MAX A. CHERNESKY

JOHN FURESZ, RALPH E. ARMSTRONG,  
GUILLERMO CONTRERAS, AND  
BRENDA WACHMANN

R. CRAINIC, B. BLONDEL, AND F. HORAUD

PAUL ALBRECHT, G. VAN STEENIS,  
A. L. VAN WEZEL, AND JONAS SALK

B. GRENIER, B. HAMZA, G. BIRON,  
C. XUEREF, F. VIARME, AND  
M. ROUMIANTZEFF

MARGARETA BÖTTIGER

A. M. McBEAN, M. L. THOMS,  
R. H. JOHNSON, B. R. GADLESS,  
B. MACDONALD, L. NERHOOD,  
P. CUMMINS, J. HUGHES, J. KINNEAR,  
C. WATTS, M. KRAFT, P. ALBRECHT,  
E. J. BOONE, M. MOORE,  
J. A. FRANK, JR., AND R. BERNIER

T. A. SWARTZ, E. BEN-PORATH,  
H. KANAANEH, L. LEITNER, AND  
N. GOLDBLUM

MARINOS C. DALAKAS, JOHN L. SEVER,  
DAVID L. MADDEN,  
NICHOLAS M. PAPADOPOULOS,  
ISABEL C. SHEKARCHI, PAUL ALBRECHT,  
AND AURELLA KREZLEWICZ

RICHARD T. JOHNSON

The Standardization of Vaccines: A Discussion  
S523

Current Advances in Viral Diagnostic Technology Applicable to  
Polio Vaccination and Diagnosis  
S525

S528

Antigenic Variation of Poliovirus Studied by Means of Mono-  
clonal Antibodies  
S535

Standardization of Poliovirus Neutralizing Antibody Tests  
S540

Seroimmunity Following Vaccination in Infants by an Inactivated  
Poliovirus Vaccine Prepared on Vero Cells  
S545

Long-Term Immunity Following Vaccination with Killed Poliovi-  
rus Vaccine in Sweden, a Country with No Circulating Poliovirus  
S548

A Comparison of the Serologic Responses to Oral and Injectable  
Trivalent Poliovirus Vaccines  
S552

Comparison of Inactivated Poliovirus Vaccine and Oral Poliovi-  
rus Vaccine Programs in Israel  
S556

Late Postpoliomyelitis Muscular Atrophy: Clinical, Virologic, and  
Immunologic Studies  
S562

Late Progression of Poliomyelitis Paralyzation: Discussion of Patho-  
genesis  
S568

SESSION V: PROSPECTS FOR WORLDWIDE CONTROL

ALFRED S. EVANS

Criteria for Assessing Accomplishment of Poliomyelitis Control  
S571

MICHAEL B. GREGG

Paralytic Poliomyelitis Can Be Eliminated  
S577

JAMES CHIN

Can Paralytic Poliomyelitis be Eliminated?  
S581

DAVID ROBINSON

Political, Administrative, and Economic Resources for the Control  
of Poliomyelitis  
S586

ANDREW L. CREESE

Priorities in Health Care: A Discussion  
S589

N. A. WARD

Practicalities of a Global Poliomyelitis Control Program  
S591

WILLIAM S. JORDAN, JR.

Prospects for Worldwide Control of Paralytic Poliomyelitis: A  
Discussion  
S594

FREDERICK C. ROBBINS

Summary and Recommendations  
S596

* * *

NOTICES  
S601